324 related articles for article (PubMed ID: 24346847)
21. [Expression and relationship of Ezh2, Runx3 and caspase-3 in endometrial adenocarcinoma].
Guo ZL; Chen K; Wang XQ; Hu W
Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):387-91. PubMed ID: 21914347
[TBL] [Abstract][Full Text] [Related]
22. GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma.
Ashton-Sager A; Paulino AF; Afify AM
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):187-92. PubMed ID: 16785788
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium.
Mitselou A; Ioachim E; Kitsou E; Vougiouklakis T; Zagorianakou N; Makrydimas G; Stefanaki S; Agnantis NJ
In Vivo; 2003; 17(5):469-77. PubMed ID: 14598611
[TBL] [Abstract][Full Text] [Related]
24. Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables.
Kyushima N; Watanabe J; Hata H; Jobo T; Kameya T; Kuramoto H
J Cancer Res Clin Oncol; 2002 Jun; 128(6):307-12. PubMed ID: 12073048
[TBL] [Abstract][Full Text] [Related]
25. Utility of PTEN expression of endometrial "surface epithelial changes" and underlying atypical endometrial hyperplasia.
Quddus MR; Ologun BA; Sung CJ; Steinhoff MM; Lawrence WD
Int J Gynecol Pathol; 2009 Sep; 28(5):471-6. PubMed ID: 19696618
[TBL] [Abstract][Full Text] [Related]
26. Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma.
Jiang XF; Tang QL; Li HG; Shen XM; Luo X; Wang XY; Lin ZQ
J Obstet Gynaecol Res; 2013 Apr; 39(4):855-63. PubMed ID: 23106983
[TBL] [Abstract][Full Text] [Related]
27. [Expression of glucose transporter-1 in endometrial hyperplasia and well-differentiated endometrioid adenocarcinoma].
Liu AJ; Hou N; Chen LZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Aug; 23(4):398-400. PubMed ID: 12940086
[TBL] [Abstract][Full Text] [Related]
28. Progesterone receptor expression and proliferative activity in uterine tumours of pet rabbits.
Vinci A; Bacci B; Benazzi C; Caldin M; Sarli G
J Comp Pathol; 2010 May; 142(4):323-7. PubMed ID: 20096851
[TBL] [Abstract][Full Text] [Related]
29. Significance of hormone receptor status and tumor vessels in normal, hyperplastic and neoplastic endometrium.
Nunobiki O; Taniguchi E; Ishii A; Tang W; Utsunomiya H; Nakamura Y; Mori I; Kakudo K
Pathol Int; 2003 Dec; 53(12):846-52. PubMed ID: 14629750
[TBL] [Abstract][Full Text] [Related]
30. Expression of astrocyte elevated gene-1: a novel marker of the pathogenesis, progression, and poor prognosis for endometrial cancer.
Song H; Li C; Lu R; Zhang Y; Geng J
Int J Gynecol Cancer; 2010 Oct; 20(7):1188-96. PubMed ID: 21495225
[TBL] [Abstract][Full Text] [Related]
31. Role of Morphometry and Matrix Metalloproteinase-9 Expression in Differentiating between Atypical Endometrial Hyperplasia and Low Grade Endometrial Adenocarcinoma.
Assaf MI; Abd El-Aal W; Mohamed SS; Yassen NN; Mohamed EA
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2291-2297. PubMed ID: 30139240
[TBL] [Abstract][Full Text] [Related]
32. Glycoprotein CD44 expression in normal, hyperplasic and neoplastic endometrium. An immunohistochemical study including correlations with p53, steroid receptor status and proliferative indices (PCNA, MIB1).
Zagorianakou N; Ioachim E; Mitselou A; Kitsou E; Zagorianakou P; Stefanaki S; Makrydimas G; Agnantis NJ
Eur J Gynaecol Oncol; 2003; 24(6):500-4. PubMed ID: 14658589
[TBL] [Abstract][Full Text] [Related]
33. Could E-Cadherin and CD10 Expression be Used to Differentiate Between Atypical Endometrial Hyperplasia and Endometrial Carcinoma?
Youssef MY; Mohamed MA
Int J Gynecol Pathol; 2019 Mar; 38(2):128-137. PubMed ID: 30726192
[TBL] [Abstract][Full Text] [Related]
34. The immunohistochemical profile of atypical eosinophilic syncytial changes vs serous carcinoma.
Haley SL; Malhotra RK; Qiu S; Eltorky ME
Ann Diagn Pathol; 2011 Dec; 15(6):402-6. PubMed ID: 21855381
[TBL] [Abstract][Full Text] [Related]
35. Different trends of p53, MDM2 and p14 ARF expression patterns in endometrial adenocarcinomas versus hyperplasia.
Buchynska LG; Nesina IP; Kashuba EV
Exp Oncol; 2007 Dec; 29(4):287-94. PubMed ID: 18199985
[TBL] [Abstract][Full Text] [Related]
36. [Assessment of the PCNA and P53 proteins expression in the proliferative, hyperplastic and neoplastic human endometrium].
Zawiślak W; Semczuk A; Miturski R
Ginekol Pol; 2001 Dec; 72(12A):1549-54. PubMed ID: 11883313
[TBL] [Abstract][Full Text] [Related]
37. Cyclin D1 and Ki-67 expression in normal, hyperplastic and neoplastic endometrium.
Shevra CR; Ghosh A; Kumar M
J Postgrad Med; 2015; 61(1):15-20. PubMed ID: 25511212
[TBL] [Abstract][Full Text] [Related]
38. Telomerase expression in normal endometrium, endometrial hyperplasia, and endometrial adenocarcinoma.
Shroyer KR; Stephens JK; Silverberg SG; Markham N; Shroyer AL; Wilson ML; Enomoto T
Int J Gynecol Pathol; 1997 Jul; 16(3):225-32. PubMed ID: 9421087
[TBL] [Abstract][Full Text] [Related]
39. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Taponeco F; Curcio C; Giuntini A; Nardini V; Fornaciari G; Artini PG; D'Ambrogio G; Genazzani AR
J Exp Clin Cancer Res; 2001 Jun; 20(2):239-46. PubMed ID: 11484981
[TBL] [Abstract][Full Text] [Related]
40. PINCH protein expression in normal endometrium, atypical endometrial hyperplasia and endometrioid endometrial carcinoma.
Zhang HZ; Li XH; Zhang X; Zhang ZY; Meng YL; Xu SW; Zheng Y; Zhu ZL; Cui DS; Huang LX; Yan BY; Sun XF
Chemotherapy; 2010; 56(4):291-7. PubMed ID: 20714146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
